Christopher Marai
Stock Analyst
(n/a)
# 4,423
Out of 4,433 analysts
19
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
12 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Buy | n/a | $31.47 | - | 2 | May 11, 2020 | |
| DCPH Deciphera Pharmaceuticals | Downgrades: Neutral | n/a | $25.45 | - | 1 | May 7, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | n/a | $147.40 | - | 3 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | n/a | $8.57 | - | 1 | Mar 30, 2020 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Buy | n/a | $44.14 | - | 1 | Mar 26, 2020 | |
| BIIB Biogen | Maintains: Buy | n/a | $235.32 | - | 1 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | n/a | $2.83 | - | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | n/a | $132.50 | - | 2 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | n/a | $21.94 | - | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | n/a | $22.39 | - | 2 | Apr 24, 2018 | |
| SLDB Solid Biosciences | Maintains: Buy | n/a | $9.69 | - | 1 | Mar 19, 2018 | |
| CLLS Cellectis | Maintains: Buy | n/a | $3.06 | - | 1 | Sep 6, 2017 |
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: n/a
Current: $31.47
Upside: -
Deciphera Pharmaceuticals
May 7, 2020
Downgrades: Neutral
Price Target: n/a
Current: $25.45
Upside: -
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: n/a
Current: $147.40
Upside: -
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: n/a
Current: $8.57
Upside: -
Corbus Pharmaceuticals Holdings
Mar 26, 2020
Initiates: Buy
Price Target: n/a
Current: $44.14
Upside: -
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: n/a
Current: $235.32
Upside: -
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: n/a
Current: $2.83
Upside: -
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: n/a
Current: $132.50
Upside: -
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: n/a
Current: $21.94
Upside: -
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: n/a
Current: $22.39
Upside: -
Solid Biosciences
Mar 19, 2018
Maintains: Buy
Price Target: n/a
Current: $9.69
Upside: -
Cellectis
Sep 6, 2017
Maintains: Buy
Price Target: n/a
Current: $3.06
Upside: -